Molecular targeting in radiotherapy of lung cancer

被引：22
作者：
Baumann, M
Krause, M
Zips, D
Petersen, C
Dittmann, K
Dörr, W
Rodemann, HP
机构：
[1] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dept Radiat Oncol, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Med Fac Carl Gustav Carus, Expt Ctr, D-01307 Dresden, Germany
[3] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, D-01307 Dresden, Germany
[4] Univ Tubingen, Dept Radiat Oncol, Sect Radiobiol & Mol Environm Res, Tubingen, Germany
来源：
LUNG CANCER | 2004年 / 45卷
关键词：
radiotherapy; tumour response; normal tissue reactions; molecular targeting; EGFR; COX-2; angiogenesis; KGF; TGF-beta; BBI; translational research; tumour growth delay; local tumour control;
D O I：
10.1016/j.lungcan.2004.07.975
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Molecular targeting is a promising option to increase the radiation response of tumours and to decrease normal tissue reactions, i.e. to achieve therapeutic gain. Molecular targeting substances in themselves are not curative while radiation is a highly efficient cytotoxic agent, with local recurrences often occurring from only few surviving clonogenic cells. High-dose radiotherapy therefore offers optimal conditions to evaluate the potential of specific biology-driven drugs for oncology. This review summarises the current status of preclinical and clinical research on combined radiation with examples of molecular targeting substances relevant for the treatment of NSCLC (EGFR, COX-2, VEGFR, KGF, TGF-beta, BBI). (C) 2004 Elsevier Science Ltd.
引用
收藏
页码：S187 / S197
页数：11
相关论文
共 120 条
  • [1] Akimoto T, 1999, CLIN CANCER RES, V5, P2884
  • [2] ALBERTI W, 1995, BRIT MED J, V311, P899
  • [3] Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy
    Andreassen, CN
    Gran, C
    Lindegaard, JC
    [J]. SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (01) : 62 - 72
  • [4] Ang KK, 2002, CANCER RES, V62, P7350
  • [5] EGFR overexpression and radiation response in glioblastoma multiforme
    Barker, FG
    Simmons, ML
    Chang, SM
    Prados, MD
    Larson, DA
    Sneed, PK
    Wara, WM
    Berger, MS
    Chen, PC
    Israel, MA
    Aldape, KD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (02): : 410 - 418
  • [6] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    Baselga, J
    Rischin, D
    Ranson, M
    Calvert, H
    Raymond, E
    Kieback, DG
    Kaye, SB
    Gianni, L
    Harris, A
    Bjork, T
    Averbuch, SD
    Feyereislova, A
    Swaisland, H
    Rojo, F
    Albanell, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) : 4292 - 4302
  • [7] RESPONSE OF HUMAN SQUAMOUS-CELL CARCINOMA XENOGRAFTS OF DIFFERENT SIZES TO IRRADIATION - RELATIONSHIP OF CLONOGENIC CELLS, CELLULAR RADIATION SENSITIVITY INVIVO, AND TUMOR RESCUING UNITS
    BAUMANN, M
    DUBOIS, W
    SUIT, HD
    [J]. RADIATION RESEARCH, 1990, 123 (03) : 325 - 330
  • [8] Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse
    Baumann, M
    Krause, M
    Zips, D
    Eicheler, W
    Dörfler, A
    Ahrens, J
    Petersen, C
    Brüchner, K
    Hilberg, F
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2003, 79 (07) : 547 - 559
  • [9] Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer
    Baumann, M
    Appold, S
    Petersen, C
    Zips, D
    Herrmann, T
    [J]. LUNG CANCER, 2001, 33 : S35 - S45
  • [10] Therapy of localized non-small cell lung cancer (take home messages)
    Baumann, M
    Stamatis, G
    Thomas, M
    [J]. LUNG CANCER, 2001, 33 : S47 - S49
12345678910